



June 17, 2019

**Clarification Memo 2  
Protocol  
Version 1.0**

**HVTN 130/HPTN 089**

**A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants**

**DAIDS-ES ID 38531**

**IND #143616—HELD BY DAIDS**

**HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN)  
Clinical Research Site (CRS) filing instructions**

Please distribute this clarification memo to all appropriate staff members, and file with your protocol documents. Consult your local Institutional Review Board (IRB)/Ethics Committee (EC) regarding submission requirements for clarification memos.

**List of changes**

- Item 1 Clarified in Sections 4.3 and 11.3.3: Enrollment in Group 4 restricted to one participant per day across all CRSs for first 6 participants ..... 2

The changes described herein will be incorporated in the next version of Protocol HVTN 130/HPTN 089 if it undergoes full protocol amendment at a later time.

**Item 1 Clarified in Sections 4.3 and 11.3.3: Enrollment in Group 4 restricted to one participant per day across all CRSs for first 6 participants**

Protocol Section 4.3, *Trial design rationale*, states that enrollment across all participating CRSs will be restricted to a maximum of 1 participant per day in Groups 1-3 and in Group 4 until 6 participants have been enrolled in each group. This is restated for Groups 1-3 at the beginning of Section 11.3.1, *Initial safety evaluation*. However, it was inadvertently omitted in Section 11.3.3, which concerns safety monitoring for Group 4 and the qualification. In addition, the important qualification that this restriction applies to Group 4 enrollment across all participating CRSs was inadvertently omitted in Section 4.3. For clarity and consistency, the 6<sup>th</sup> paragraph in Section 4.3 and the first paragraph in Section 11.3.3 have been revised as shown below (added text in **bold underline**).

**Revised:**

**4.3 Trial design rationale**

....

Following approval by the PSRT, Group 4 will begin to enroll. Enrollment **across all participating CRSs** will be restricted to a maximum of one participant per day for the first 6 participants. Cumulative safety data will be reviewed daily by HVTN clinical safety staff (ie, Clinical Safety Specialist nurses and physicians) and reviewed at least weekly by the HVTN 130/HPTN 089 PSRT.

**11.3.3 Safety considerations for Group 4**

**Enrollment across all participating CRSs will be restricted to a maximum of one participant per day for the first 6 participants.** In addition to monitoring participant safety throughout the study period, the HVTN130/HPTN 089 PSRT will review cumulative safety data available on the first 6 participants in Group 4 up to and including the 2-week visit after the first study product administration to determine whether the remaining participants in Group 4 can be enrolled. If any Grade 3 or higher AEs deemed related to study product are reported in Group 4, the HVTN SMB will perform an additional review of these safety data to make the final determination based on safety for proceeding with enrollment of the remaining 3 participants in Group 4. The HVTN130/HPTN 089 PSRT may consult with the HVTN SMB on an ad hoc basis for these evaluations.

## Protocol modification history

Protocol modifications are made to HVTN protocols via clarification memos, letters of amendment, or full protocol amendments. HVTN protocols are modified and distributed according to the standard HVTN procedures as described in the HVTN Manual of Operations (MOP).

The version history of, and modifications to, Protocol HVTN 130/HPTN 089 are described below.

### **Date: June 17, 2019**

---

*Protocol version: Version 1.0*

*Protocol modification: Clarification Memo 2*

- Item 1 Clarified in Sections 4.3 and 11.3.3: Enrollment in Group 4 restricted to one participant per day across all CRSs for first 6 participants

### **Date: May 22, 2019**

---

*Protocol version: Version 1.0*

*Protocol modification: Clarification Memo 1*

- Item 1 Corrected in Section 8.3.1.2, *PGT121 intravenous infusion preparation*, Section 8.3.4.2, *VRC07-523LS intravenous infusion preparation*, and Section 8.5, *Acquisition of study products*: Typographical errors related to Sodium Chloride for Injection, 0.9% USP
- Item 2 Added to Title page: IND number

### **Date: April 04, 2019**

---

*Protocol version: Version 1.0*

*Protocol modification: NA*

Original protocol